Cervical and ovarian carcinoma
Conditions
Interventions
chemoradiotherapy:Chemotherapy and/or Radiotherapy
Immnotherapy:Chemotherapy and/or Radiotherapy with Immnotherapy
Sponsors
The second affiliated hospital,Zhengzhou University
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Overian or cervical cancer confirmed by post-surgery histopathology (or cytological diagnosis); 2. Aged 18~75years; 3. KPS=70; The expected survival time is more than 3 months; 4. The liver, kidney, marrow function is almost normal: WBC=3.5×1069/L, Hb=90g/L, PLT=90×10^9/L; SCr=1.5, Serum TBIL=1.5 times of the normal limit, ALT, AST=2.5 times of the normal limit, ALT/AST=5 times of the normal limit in patients with liver metastasis; 5. The patients can be obtained a certain number of tumor tissue through surgical treatment or other method; 6. Voluntary participation in the clinical trials and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Vital organs (heart, liver, kidney) function is serious dysfunction; 2. Metastatic area>50% of liver volum; 3. Patients received organ transplantation; 4. Patients with other malignant tumors or have occurred brain metastasis; 5. Patients with history of autoimmune disease; 6. Patients in pregnancy or breast-feeding period (women of child-bearing age need to check pregnancy test); 7. Patients with acute infection disease or in chronic active stage; 8. Patients with clear history of drug allergy or belong to allergic constitution; 9. Patients received chemotherapy, radiation therapy, immunosuppressive drugs (cyclosporine A, etc.) or other immune treatment in 4 weeks; 10. Patients received other clinical trials in 4 weeks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| subsets of lymphocytes in PBMC;regulator T cell in PBMC;suppressor T cell in PBMC;median survival time;overall survival;Progression free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| molecular markers in serum; | — |
Countries
China
Contacts
Public ContactFeng Chang-wei
The second affiliated hospital, Zhengzhou University
Outcome results
None listed